Lilly Oncology

There’s a time when everything changes. That life-altering moment when someone hears, “You have cancer.” That moment is what motivates everyone at Lilly Oncology.

Patient TruAssist Program

PatientOne Assistance Program

Bridging the Biomarker Gaps Resources

Did you know?

More than 152,000 Florida residents will face a new cancer diagnosis this year. Each of these cases is unique, but there’s one thing everyone has in common: the right to precision care.

Biomarker testing gives you more knowledge and helps empower well-informed treatment decisions.

Click Here for helpful resources about biomarker testing.

Lung:

To help reduce disparities in biomarker testing, Lilly is offering no-cost, comprehensive next-generation sequencing (NGS) tests for eligible patients with advanced or metastatic non-small cell lung cancer (NSCLC).

The full cost of the test is covered regardless of test results or treatment decisions. No patient, healthcare provider, or insurance company will be billed for any test ordered through the Lung Cancer NGS Program.

Determine if your eligible patients with advanced or metastatic NSCLC have actionable biomarkers—at no cost to them.

To request a test for your patient, click here.

Thyroid:

To help reduce disparities in biomarker testing, Lilly is offering no-cost, comprehensive next-generation sequencing (NGS) tests for eligible patients who have advanced or metastatic medullary thyroid cancer (MTC) or non-medullary thyroid cancer (non-MTC).

The full cost of the test is covered regardless of test results or treatment decisions. No patient, healthcare provider, or insurance company will be billed for any test ordered through the Thyroid Cancer NGS Program.

Determine if your eligible patients with advanced or metastatic MTC or non-MTC have actionable biomarkers—at no cost to them.

To request a test for your patient, click here.

Both:

Testing for the presence of molecular biomarkers can help pinpoint precise treatment options targeted to a patient’s particular cancer. To help reduce disparities in biomarker testing, Lilly is offering no-cost, comprehensive next-generation sequencing (NGS) tests for eligible patients who have:

• Advanced or metastatic non-small cell lung cancer (NSCLC); and,
• Advanced or metastatic medullary thyroid cancer (MTC) or non-medullary thyroid cancer (non-MTC).

The full cost of the test is covered regardless of test results or treatment decisions. No patient, healthcare provider, or insurance company will be billed for any test ordered through the Lung Cancer NGS Program or Thyroid Cancer NGS Program.

Determine if your eligible patients with advanced or metastatic NSCLC, MTC, or non-MTC have actionable biomarkers—at no cost to them.

To request a test for your NSCLC patient, click here. 

To request a test for your MTC or non-MTC patient, click here.